New Approach to Parkinson s Disease: Synuclein Immunotherapy

Size: px
Start display at page:

Download "New Approach to Parkinson s Disease: Synuclein Immunotherapy"

Transcription

1 RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc

2 Primary Motor and Non-Motor Symptoms of Parkinson s Disease Motor Symptoms Bradykinesia (slow movements) Muscle Rigidity Postural Instability (poor balance) Tremor at Rest Non-Motor Symptoms Loss of olfaction REM Behavioral Sleep Disorder Autonomic nervous system (e.g., orthostatic hypotension) Constipation Cognitive changes 2

3 3 Neurotransmitter Basis for Motor Symptoms in Parkinson s Disease

4 Genes identified that are implicated in Parkinsonism 4

5 -Synuclein Abnormally Accumulates in Several Neurodegenerative Disorders Familial Parkinson s disease Alzheimer s disease -synuclein Trojanowski et al NBIA-1 Multiple system atrophy Masliah et al Lewy body disease Wakabayashi et al Galvin et al Takeda et al; Spillantini et al 5

6 Scientific evidence supporting the anti- synuclein immunotherapy for Parkinson s Disease -synuclein pathology strongly implicated in Parkinson s Disease Accumulation of -synuclein is a predominant neuropathological feature and it follows the topological progression of disease Genetic evidence favors a prominent role for -synuclein in disease: missense mutations, duplication/triplication of non-mutated (D/R) -synuclein as an extracellular target during pathogenesis Caudal-rostral staging suggests transynaptic spreading Host-to-graft transfer of -synuclein pathology in transplants Several intercellular -synuclein propagation models described Passive anti- -synuclein immunization is a viable disease-modifying therapy for PD -synuclein is not deposited extracellularly in PD and safety/dose-limiting concerns are not anticipated Preclinical efficacy in various in vivo -synucleinopathy models 6 6 8/19/2014

7 Hypothesis: -Synuclein Immunotherapy May Reduce Neuronal Toxicity and Prevent Cell-to-Cell Transfer Synaptic Loss and Pathogenic Spread Antibodies Reduce Pathogenic Spread and Decrease Synuclein Pathology 7

8 In Vitro Findings

9 PRX002 Immunoreacts with Lewy Pathology Tg mice brain (Line 61) Human brain (DLB) Lewy body PRX002 9E4 9E4 9 PRX002 PRX002 immunoreacts with Lewy bodies and Lewy neurites in brains of PD and DLB patients.

10 Murine Precursor of PRX002 Demonstrates Preferential Binding to Aggregates Over Monomeric -synuclein Competition of Monomeric Biotinylated Synuclein By Equal Mass of Monomeric or Aggregated (fibrillar) Synuclein Competition ELISA-Ability of equal mass of aggregated -synuclein versus monomeric -synuclein to displace biotinylated monomeric -synuclein 10

11 Antibodies Block Cell-to-Cell Transmission of - synuclein In Vitro in Concentration- and Epitope- Dependent Manner IgG1 g/ml g/ml 9E4 11 Games et al., 2014

12 C-terminal Cleaved -synuclein FL- -syn Syn105 Nucleus -C-terminally cleaved species of -synuclein are thought to contribute to increased -synuclein oligomerization and toxicity. -Prothena generated a novel antibody (SYN105) against the c- terminally truncated sequence (aa s ) of -synuclein. -Syn105 labels Lewy bodies/neurites and dystrophic neurites in brains of PD/DLB and -synuclein transgenic mice, but not brains of control subjects and wild-type mice. 12 Games et al., 2013

13 Blockade of Calpain-induced -synuclein Truncation by Antibodies is Epitope-specific monomer 13 Games et al., 2014

14 In Vivo Findings

15 Efficacy of Anti-synuclein Immunotherapy has been Reported in Various Models of Synucleinopathy Transgenic D-Line mice (PDGFβ promoter, Masliah et al.) -Moderate levels of human -syn (nonmutated). -Highest expression in neocortical and limbic system -Intracellular inclusions, motor deficits, dopamine loss Transgenic Line61 mice (mthy1 promoter, Masliah et al.) High and widespread human -syn (nonmutated) expression in CNS and PNS. Inclusions in cortex, hippocampus, basal ganglia, cerebellum. Mild nigrostriatal deficit at old age (>12mo). Non-motor deficits: olfactory, gastrointestinal, circadian, cognitive. Intracerebral injection of synthetic -synuclein fibrils (V.Lee et al.) Recruitment of endogenous -syn to form inclusions in cortex, hippocampus, basal ganglia, cerebellum. Temporal and spatial spread of -syn pathology Motoric deficits and loss of dopaminergic neurons in the substantia nigra. 15

16 Passive Immunization Promotes Clearance of -synuclein Aggregates, Protects Against Synaptic Loss, and Reduces Behavior Deficits in Line-D Transgenic Mice Line-D mice (6-month-old) received weekly IP injections (10 mg/kg) for 6 months with the carboxy terminus α-syn antibodies (9E4, 8A5) or amino terminus α-syn antibody (6H7) and IgG1 control (27-1). α-synuclein Loss of Synapses Behavior Deficit PSDs (EM) Insoluble Aggregates PSD95 (WB) 16 Masliah et al., 2011

17 Passive Immunization Promotes Clearance of -synuclein Aggregates, Protects Against Synaptic Loss, and Reduces Behavior Deficits in Line-61 Transgenic Mice Line-61 mice (3-month-old) received weekly IP injections (10 mg/kg) for 5 months with the carboxy terminus α-syn antibodies (9E4, 5C1, 5D12) or mid-region α-syn antibody (1H7) and IgG1 control (27-1). α-synuclein Pathology Loss of Synapses Behavior Deficit IgG1 9E4 Correct quadrant 25 IgG1 9E4 Time (sec) * 17 Games et al., 2014

18 Immunotherapy Blocks Uptake/Transmission of -synuclein Fibrils In Vivo Preservation of Neurons Blockade of Synuclein Uptake/Transmission Behavior Improvement Tran et al.,

19 Summary of Preclinical Efficacy Studies with Anti- -synuclein Antibodies Anti- -synuclein immunotherapy was demonstrated in various animal models of synucleinopathy to promote: Reduction of -syn aggregates and uptake/transmission by neurons Synaptic/Neuronal Loss and Pathological Spread Reduction of gliosis Preservation of synaptic integrity Amelioration of motor, cognitive, and sensorimotor behavioral deficits Antibodies neutralize and clear pathogenic synuclein The proposed MoA for antibodies are: 1) Neutralization and clearance of pathologenic -synuclein 2) Blockade of CT-cleavage by calpain 19

20 Efficacy of Immunotherapy in Models of Synucleinopathy IgG1 Blockade of cell-to-cell transmission IgG1 Lowering of -syn Pathology 9E4 9E4 mab g/ml) Improvement in Behavior (water maze) IgG1 Protection of Synapses 9E4 Proposed MoA s: -Neutralization -Clearance -Disaggregation -Blockade of calpain cleavage 9E4 20

21 Current Clinical Status of PRX002 Prothena and Roche entered into worldwide collaboration to co-develop and co-promote antibodies for treatment of Parkinson's disease. Ongoing double blind Single Ascending dose study in healthy volunteers Ongoing double blind Multiple ascending dose study in Parkinson s patients 21

22 Prothena Vision We target proteins in novel ways to resolve unmet clinical need in patients 22

23 Acknowledgements Dora Games Peter Seubert Robin Barbour Ronald Torres Lana Alexander Patricia Sacayon Wagner Zago Eliezer Masliah Edward Rockenstein Manuel Buttini Michael Mante Brian Spencer Anthony Adame Christina Patrick Elvira Valera Kiren Ubhi Silke Nuber Sarah Mueller-Steiner 23

Prothena Corporation plc Overview

Prothena Corporation plc Overview November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ Forward-Looking Statements This presentation contains forward-looking statements. These

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

Treatment of Neurological Disorders. David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018

Treatment of Neurological Disorders. David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018 Treatment of Neurological Disorders David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018 1 Corporate Overview Developing first-in-class therapies to treat orphan and non-orphan

More information

Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice

Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Nolwen L. Rey, PhD Patrik Brundin s Laboratory, Van Andel Research Institute Grand Rapids, Michigan, USA 15th Annual

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche

Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche LA NEUROSONOLOGIA NELLE PATOLOGIE DEGENERATIVE E VASCOLARI CEREBRALI San Benedetto del Tronto 6-8 novembre 2017 Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche Giuseppe De Michele

More information

Modeling Parkinson s disease: systems to test gene-environment interactions

Modeling Parkinson s disease: systems to test gene-environment interactions Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)

More information

The Parkinson s You Can t See

The Parkinson s You Can t See The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?

More information

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,

More information

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:

More information

2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease

2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease inherited forms of PD The Pathogenesis of Parkinson s Disease February, 2013 PARK1 dominant α-synuclein presynaptic protein PARK2 recessive parkin E3 ubiquitin ligase PARK3 dominant 2p13? PARK4 dominant

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?

More information

Investor Presentation

Investor Presentation Investor Presentation April 2019 Mr Geoffrey Kempler CEO and Chairman Dr David Stamler Chief Medical Officer & SVP Clinical Development AN ALTERNATE FUTURE We exist to create an alternate future for people

More information

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the

More information

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with

More information

Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide

Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal

More information

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are

More information

Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter

Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter Impairment of Neurogensis in the Olfactory Bulb of Transgenic Mice Overexpressing Human Wildtype Alpha Synuclein Under the Thy-1 Promoter Parkinson s disease (PD) is a progressive neurodegenerative disorder

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

Classes of Neurotransmitters. Neurotransmitters

Classes of Neurotransmitters. Neurotransmitters 1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters

More information

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.

More information

FDG-PET e parkinsonismi

FDG-PET e parkinsonismi Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism

More information

Stem Cells and the Study of Neurodegeneration. Tracy Young-Pearse, PhD September 12, 2014!

Stem Cells and the Study of Neurodegeneration. Tracy Young-Pearse, PhD September 12, 2014! Stem Cells and the Study of Neurodegeneration Tracy Young-Pearse, PhD September 12, 2014! Techniques for studying mechanisms of neurological disease Animal models Human subjects Postmortem analyses, imaging

More information

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -

More information

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci. How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic

More information

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE 1 GENERAL INTRODUCTION GENERAL INTRODUCTION PARKINSON S DISEASE Parkinson s disease (PD) is a neurodegenerative movement disorder, named after James Parkinson who described some of its characteristic

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

ALZHEIMER S DISEASE FACTOIDS & STATISTICS

ALZHEIMER S DISEASE FACTOIDS & STATISTICS ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10

More information

Pietro Cortelli. IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna

Pietro Cortelli. IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna Pietro Cortelli IRCCS Istituto delle Scienze Neurologiche di Bologna DIBINEM, Alma Mater Studiorum - Università di Bologna HYSTORY 1900 description of OPCA (Dejerine, Thomas) 1960 description of Shy-Drager

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

Strategies for Neurorestoration: Growth Factors

Strategies for Neurorestoration: Growth Factors Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases

More information

Research on Cannabis and PD: Is there any evidence?

Research on Cannabis and PD: Is there any evidence? Research on Cannabis and PD: Is there any evidence? Benzi M. Kluger, MD, MS Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver DISCLOSURES

More information

UNDERSTANDING PARKINSON S DISEASE

UNDERSTANDING PARKINSON S DISEASE UNDERSTANDING PARKINSON S DISEASE WHAT IS PARKINSON S DISEASE? A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middleaged

More information

Investigating molecular mechanisms of progression of Parkinson s Disease in human brain

Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Alzheimer s disease (AD) is the most

Alzheimer s disease (AD) is the most Therapeutic development for Alzheimer s disease at Eli Lilly and Company AUTHORS Michael Hutton 1, Michael Irizarry 2, Mark Mintun 3, Phyllis Ferrell 2, Eric Siemers 2, Christer Nordstedt 2 & Ronald DeMattos

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

Study Guide Unit 2 Psych 2022, Fall 2003

Study Guide Unit 2 Psych 2022, Fall 2003 Study Guide Unit 2 Psych 2022, Fall 2003 Subcortical Anatomy 1. Be able to locate the following structures and be able to indicate whether they are located in the forebrain, diencephalon, midbrain, pons,

More information

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

Prothena Corporation plc R&D Day. November 16, 2017

Prothena Corporation plc R&D Day. November 16, 2017 Prothena Corporation plc R&D Day November 16, 2017 Gene Kinney, PhD President & Chief Executive Officer Forward-Looking Statements This presentation contains forward-looking statements. These statements

More information

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a

More information

Delirium & Dementia. Nicholas J. Silvestri, MD

Delirium & Dementia. Nicholas J. Silvestri, MD Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts

More information

Ch. 45 Continues (Have You Read Ch. 45 yet?) u Central Nervous System Synapses - Synaptic functions of neurons - Information transmission via nerve

Ch. 45 Continues (Have You Read Ch. 45 yet?) u Central Nervous System Synapses - Synaptic functions of neurons - Information transmission via nerve Ch. 45 Continues (Have You Read Ch. 45 yet?) u Central Nervous System Synapses - Synaptic functions of neurons - Information transmission via nerve impulses - Impulse may be blocked in its transmission

More information

Diana L. Price 1, Edward Rockenstein 2, Douglas Bonhaus 1, Eliezer Masliah 2. Abstract

Diana L. Price 1, Edward Rockenstein 2, Douglas Bonhaus 1, Eliezer Masliah 2. Abstract Validation of retinal imaging for characterizing alpha-synuclein-egfp deposition in a transgenic mouse model of Parkinson s Disease/Dementia with Lewy Bodies Diana L. Price 1, Edward Rockenstein 2, Douglas

More information

Prothena Corporation plc

Prothena Corporation plc Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and

More information

Course Calendar

Course Calendar Clinical Neuroscience BMS 6706C Charles, Ph.D., Course Director charles.ouimet@med.fsu.edu (850) 644-2271 2004 2005 Course Calendar Click here to return to the syllabus Meeting Hours for entire semester:

More information

MOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement

MOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement MOVEMENT 2 Dr. Steinmetz 3 OUTLINE The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement Parkinson s Disease Huntington s Disease 1 4 TYPES

More information

Dementia and Healthy Ageing : is the pathology any different?

Dementia and Healthy Ageing : is the pathology any different? Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association

More information

Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation

Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation Article Published Version Creative Commons: Attribution 4.0 (CC BY) Open Access

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

9.01 Introduction to Neuroscience Fall 2007

9.01 Introduction to Neuroscience Fall 2007 MIT OpenCourseWare http://ocw.mit.edu 9.01 Introduction to Neuroscience Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. 9.01 Recitation (R02)

More information

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal

More information

Novel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology

Novel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant

More information

Course Calendar - Neuroscience

Course Calendar - Neuroscience 2006-2007 Course Calendar - Neuroscience Meeting Hours for entire semester: Monday - Friday 1:00-2:20 p.m. Room 1200, COM August 28 August 29 August 30 August 31 September 1 Course introduction, Neurocytology:

More information

Basal Ganglia General Info

Basal Ganglia General Info Basal Ganglia General Info Neural clusters in peripheral nervous system are ganglia. In the central nervous system, they are called nuclei. Should be called Basal Nuclei but usually called Basal Ganglia.

More information

Parkinson s UK Brain Bank

Parkinson s UK Brain Bank Parkinson s UK Brain Bank From Brain to Breakthrough Dr George Gveric Manager 19 October 2018 Coordinated approach Donors Relatives Information Reporting Researchers Tissue supply Quality assurance Expertise

More information

Sharon Shacham, Ph.D. ICAD, July 29th, 2008 NASDAQ: EPIX

Sharon Shacham, Ph.D. ICAD, July 29th, 2008 NASDAQ: EPIX Stimulation of Serotonin Type 4 Receptors Leads to Increases in Alpha-Secreatase Activity and sappalpha: Potential for Disease Modification in Alzheimer's Disease Sharon Shacham, Ph.D. ICAD, July 29th,

More information

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000

More information

Chemical Control of Behavior and Brain 1 of 9

Chemical Control of Behavior and Brain 1 of 9 Chemical Control of Behavior and Brain 1 of 9 I) INTRO A) Nervous system discussed so far 1) Specific 2) Fast B) Other systems extended in space and time 1) Nonspecific 2) Slow C) Three components that

More information

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative Samay Jain, MD MSc Seo Young Park, PhD University of Pittsburgh Department of Neurology and Center for Research

More information

Chapter 17. Nervous System Nervous systems receive sensory input, interpret it, and send out appropriate commands. !

Chapter 17. Nervous System Nervous systems receive sensory input, interpret it, and send out appropriate commands. ! Chapter 17 Sensory receptor Sensory input Integration Nervous System Motor output Brain and spinal cord Effector cells Peripheral nervous system (PNS) Central nervous system (CNS) 28.1 Nervous systems

More information

A Progressive Mouse Model of Parkinson s Disease: The Thy1-aSyn ( Line 61 ) Mice

A Progressive Mouse Model of Parkinson s Disease: The Thy1-aSyn ( Line 61 ) Mice Neurotherapeutics (2012) 9:297 314 DOI 10.1007/s13311-012-0104-2 REVIEW A Progressive Mouse Model of Parkinson s Disease: The Thy1-aSyn ( Line 61 ) Mice Marie-Francoise Chesselet & Franziska Richter &

More information

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Ken Marek Coalition Against Major Diseases and FDA 2014 Annual Scientific Workshop Oct 2014 Disclosure Co-founder

More information

Kurt A. Jellinger. 2 nd Int. Conference BrainNet Europe, Munich, Dec , 2008 NAC A30P A53T ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH

Kurt A. Jellinger. 2 nd Int. Conference BrainNet Europe, Munich, Dec , 2008 NAC A30P A53T ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH 2 nd Int. Conference BrainNet Europe, Munich, Dec. 10-12, 2008 NH 3 1 NAC 125 133 136 A30P A53T 125 140 ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH 29 71 82 125 129 (Src) (GRK5, CK-1 & CK-2) Kurt A.

More information

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010 Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate

More information

Update on functional brain imaging in Movement Disorders

Update on functional brain imaging in Movement Disorders Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF

More information

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

First described by James Parkinson in his classic 1817 monograph, An Essay on the Shaking Palsy Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive

More information

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ¹ University of Medicine and Pharmacy Cluj-Napoca ² Clinical Rehabilitation Hospital

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

Chapter 12 Nervous Tissue

Chapter 12 Nervous Tissue 9/12/11 Chapter 12 Nervous Tissue Overview of the nervous system Cells of the nervous system Electrophysiology of neurons Synapses Neural integration Subdivisions of the Nervous System 1 Subdivisions of

More information

Exam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system

Exam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system Exam 2 PSYC 2022 Fall 1998 (2 points) What 2 nuclei are collectively called the striatum? (2 points) Match a brain structure that is located closest to the following portions of the ventricular system

More information

Overview of neurological changes in Alzheimer s disease. Eric Karran

Overview of neurological changes in Alzheimer s disease. Eric Karran Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,

More information

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies) Dementia with Lewy bodies First described: Okazaki H, 1961, Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp

More information

Comprehensive Approach to DLB Management

Comprehensive Approach to DLB Management Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures

More information

DEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD

DEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PARKINSON`S DISEASE DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PD The concept of Non Motor Symptoms in PD Dementia in Parkinson`s

More information

Kinematic Modeling in Parkinson s Disease

Kinematic Modeling in Parkinson s Disease Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing

More information

212 Index C-SB-13,

212 Index C-SB-13, Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration

More information

Basal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota

Basal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals

More information

Action potentials propagate down their axon

Action potentials propagate down their axon Action potentials propagate down their axon Larger diameter axons have less resistance to ion flow Speed of conduction is faster in large diameter axons Saltatory conduction in myelinated axons Large myelinated

More information

The Marmoset Monkey as Model for Neurological Disorders

The Marmoset Monkey as Model for Neurological Disorders The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog

More information

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information

Receptors and Neurotransmitters: It Sounds Greek to Me. Agenda. What We Know About Pain 9/7/2012

Receptors and Neurotransmitters: It Sounds Greek to Me. Agenda. What We Know About Pain 9/7/2012 Receptors and Neurotransmitters: It Sounds Greek to Me Cathy Carlson, PhD, RN Northern Illinois University Agenda We will be going through this lecture on basic pain physiology using analogies, mnemonics,

More information

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS

More information

The neurvous system senses, interprets, and responds to changes in the environment. Two types of cells makes this possible:

The neurvous system senses, interprets, and responds to changes in the environment. Two types of cells makes this possible: NERVOUS SYSTEM The neurvous system senses, interprets, and responds to changes in the environment. Two types of cells makes this possible: the neuron and the supporting cells ("glial cells"). Neuron Neurons

More information

Neural Communication. Central Nervous System Peripheral Nervous System. Communication in the Nervous System. 4 Common Components of a Neuron

Neural Communication. Central Nervous System Peripheral Nervous System. Communication in the Nervous System. 4 Common Components of a Neuron Neural Communication Overview of CNS / PNS Electrical Signaling Chemical Signaling Central Nervous System Peripheral Nervous System Somatic = sensory & motor Autonomic = arousal state Parasympathetic =

More information

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

MAXIMIZING FUNCTION IN PARKINSON S DISEASE 1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):

More information

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.

More information

Clinical Features and Treatment of Parkinson s Disease

Clinical Features and Treatment of Parkinson s Disease Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and

More information

The motor regulator. 1) Basal ganglia/nucleus

The motor regulator. 1) Basal ganglia/nucleus The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits

More information

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age

More information

Making Things Happen 2: Motor Disorders

Making Things Happen 2: Motor Disorders Making Things Happen 2: Motor Disorders How Your Brain Works Prof. Jan Schnupp wschnupp@cityu.edu.hk HowYourBrainWorks.net On the Menu in This Lecture In the previous lecture we saw how motor cortex and

More information

Dr. Farah Nabil Abbas. MBChB, MSc, PhD

Dr. Farah Nabil Abbas. MBChB, MSc, PhD Dr. Farah Nabil Abbas MBChB, MSc, PhD The Basal Ganglia *Functions in association with motor cortex and corticospinal pathways. *Regarded as accessory motor system besides cerebellum. *Receive most of

More information

Lewy Bodies in the Amygdala

Lewy Bodies in the Amygdala ORIGINAL CONTRIBUTION Lewy Bodies in the Amygdala Increase of -Synuclein Aggregates in Neurodegenerative Diseases With Tau-Based Inclusions Anca Popescu, MD; Carol F. Lippa, MD; Virginia M.-Y. Lee, PhD;

More information

Using Sources in the GDP

Using Sources in the GDP Using Sources in the GDP The following are five examples of sources that you may encounter while working on your GDP project. The information contained in each of these sources (shown by screen shot) was

More information

Nervous System. 1. What N.S. division controls skeletal muscles? 3. What kind of neuroglia myelinates axons in the PNS?

Nervous System. 1. What N.S. division controls skeletal muscles? 3. What kind of neuroglia myelinates axons in the PNS? . What N.S. division controls skeletal muscles? Nervous System SRS Review %. Central nervous system %. Peripheral nervous system %. Afferent division %. Somatic division %. Autonomic division %. Sympathetic

More information

Pushing the plasticity: The role of exercise in the management of neurological illness

Pushing the plasticity: The role of exercise in the management of neurological illness Pushing the plasticity: The role of exercise in the management of neurological illness Michael Gaetz Ph.D. Associate Professor, Kinesiology Department Faculty of Health Sciences University of the Fraser

More information